Please ensure Javascript is enabled for purposes of website accessibility

Amarin's Vascepa Sales Jump 34% in Q2 Despite COVID-19 Headwinds

By Keith Speights - Aug 4, 2020 at 11:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big wild card for the company now is its appeal of a court ruling invalidating key patents for the high triglyceride drug.

It's been a downright miserable year for Amarin (AMRN 5.23%) so far. The stock imploded earlier this year after a judge invalidated key patents for hypertriglyceridemia drug Vascepa. And Amarin's shares are still down nearly 70% year to date.

Investors hoped for at least a little bit of good news when Amarin announced its second-quarter results before the market opened on Tuesday. That's what they got. Here are the highlights from Amarin's Q2 update.

Fish oil pill with heart wave and tiny heart printed on it

Image source: Getty Images.

By the numbers

Amarin reported revenue of $135.3 million in the second quarter, a 34% increase from the $100.8 million reported in the prior-year period. However, this revenue total fell well below the average analysts' revenue estimate of $149.5 million.

The drugmaker announced net income in the second quarter of $4.4 million, or $0.01 per share, based on generally accepted accounting principles (GAAP). This reflected significant improvement from Amarin's GAAP net loss of $1.8 million, or $0.01 per share, posted in the same period of 2019.

Amarin recorded adjusted net income of $16.5 million, or $0.04 per share, compared with $6.1 million, or $0.02 per share, in the same period in 2019. This beat the consensus Wall Street estimate of a net loss of $0.07 per share.

Behind the numbers

Although Amarin's revenue increased from the prior-year period, growth wasn't as robust as hoped because of a simple reason: COVID-19. Patient visits fell dramatically in the wake of shelter-in-place restrictions due to the coronavirus pandemic. Because physicians typically prescribe drugs after office visits and blood tests, the lower number of visits caused sales of Vascepa to plunge.

It also didn't help that Amarin's sales team couldn't promote Vascepa face-to-face with healthcare professionals. Although Amarin used virtual interactions with physicians and other prescribers, these efforts weren't as effective as personal visits.

Amarin's bottom line improved significantly, though. The increase in revenue was a key factor. The company's operating expenses rose by 27% year over year to $102.4 million, a slower rate of growth than its revenue growth.

Looking ahead

CEO John F. Thero stated, "The second quarter of 2020 was a challenging but productive quarter for Amarin. Despite headwinds brought on by the adverse patent judgment and the onset of COVID-19 related societal restrictions at the end of the first quarter, the Amarin team continues to be productive with an increasingly positive outlook."

One reason for the "increasingly positive outlook" mentioned by Thero is that patient visits to physicians are increasing. However, Amarin cited IQVIA data showing that patient visits to physicians are still roughly 35% lower than pre-COVID-19 levels.

The company anticipates that its partner in China will report results from a clinical trial of Vascepa later this year. Amarin also continues to expect European approval of Vascepa in early 2021.

But the biggest potential catalyst for the biotech stock is the possibility that it could win an appeal of the district court decision invalidating key patents for Vascepa. A hearing for Amarin's appeal to the U.S. Court of Appeals is scheduled for Sept. 2, 2020.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.61 (5.23%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.